Pharsight

Quviviq generic

Quviviq is an insomnia treatment drug owned by Idorsia. It contains daridorexant hydrochloride as the active ingredient and is available in tablet form for oral intake. Quviviq was first authorized for market use on April 7, 2022.

When will Quviviq generic be available?

The generic versions of Quviviq are projected to be released after December 2, 2034. Although the drug can face patent challenges from April 7, 2026, the patent that could majorly affect the availability of the generic version of Quviviq is patent number US10023560 titled 'Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist', which expires on December 2, 2034.

Quviviq uses

Quviviq is primarily used for the treatment of insomnia. Its active ingredient, daridorexant hydrochloride, works by blocking the action of a hormone called orexin, which is known to keep people awake. By blocking this hormone, it promotes sleep and helps reduce insomnia symptoms.

Quviviq patent expiration

Quviviq holds a total of 3 patents, the critical one being 'US10023560' which expires on December 2, 2034. This patent is expected to majorly impact the release date of Quviviq's generic versions. Below are the details of the patent:

Quviviq dosage

Want to ask something?